Of course, this topic may not be funny for much longer given 40,000 recently announced job cuts by Johnson & Johnson, Pfizer, and Astra-Zeneca or the 16,000 cuts planned by Merck.
Thursday, November 05, 2009
Dilbert on Drug Marketing
As a follow-up to Tuesday's post, management guru Scott Adams shows how promotion by a pharmaceutical manufacturer affects physicians' prescribing decisions.
Of course, this topic may not be funny for much longer given 40,000 recently announced job cuts by Johnson & Johnson, Pfizer, and Astra-Zeneca or the 16,000 cuts planned by Merck.
Of course, this topic may not be funny for much longer given 40,000 recently announced job cuts by Johnson & Johnson, Pfizer, and Astra-Zeneca or the 16,000 cuts planned by Merck.
Adam...has H1N1 got you homebound?
ReplyDeleteThought you'd be on top of the FTC investigation into CVS/Caremark by now. Not that is truly any new news to some of us. Guess Walgreens might be the stock to watch...we'll see.